Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate/Metformin vs Rosiglitazone in T2DM and Dyslipidemia
NCT00361868Phase 3Terminated
- Sponsor
- Solvay
- Start
- Jun 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate and metformin in type 2 diabetes mellitus (T2DM) and dyslipidemia (2 arms), sponsored by Solvay. Primary endpoint: Hemoglobin A1c and Triglycerides at 24 weeks. Started Jun 2006; status: terminated.
02
Drugs
fenofibratemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT00361868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361868.